Seres Therapeutics, Inc. (MCRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
MCRB POWR Grades
- MCRB scores best on the Value dimension, with a Value rank ahead of 52.57% of US stocks.
- MCRB's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- MCRB's current lowest rank is in the Growth metric (where it is better than 5.94% of US stocks).
MCRB Stock Summary
- Of note is the ratio of Seres Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 13.67% of US stocks have a lower such ratio.
- MCRB's price/sales ratio is 69.29; that's higher than the P/S ratio of 95.37% of US stocks.
- Seres Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -14.07%, greater than the shareholder yield of only 16.11% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Seres Therapeutics Inc are PIRS, AKBA, MRUS, INSM, and LQDA.
- MCRB's SEC filings can be seen here. And to visit Seres Therapeutics Inc's official web site, go to www.serestherapeutics.com.
MCRB Stock Price Chart Interactive Chart >
MCRB Price/Volume Stats
|Current price||$23.25||52-week high||$38.50|
|Prev. close||$23.33||52-week low||$3.67|
|Day high||$24.00||Avg. volume||920,832|
|50-day MA||$20.93||Dividend yield||N/A|
|200-day MA||$24.67||Market Cap||2.13B|
Seres Therapeutics, Inc. (MCRB) Company Bio
Seres Therapeutics is a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company was founded in 2010 and is based in Cambridge, Massachusetts.
MCRB Latest News Stream
|Loading, please wait...|
MCRB Latest Social Stream
View Full MCRB Social Stream
Latest MCRB News From Around the Web
Below are the latest news stories about Seres Therapeutics Inc that investors may wish to consider to help them evaluate MCRB as an investment opportunity.
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative
Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Terri Young, Ph.D., R.Ph., Chief Commercial and Strategy Officer of Seres Therapeutics, will present at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:00 p.m. ET.
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis (UC) on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET.
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Köln, Germany) demonstrating that decreased microbiome diversity in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is associated with poor clinical outcomes including mortality and increased incidence of intestinal graft-versus-host disease (GvHD). The data are being presented in an oral presentation at the 2021 Am
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Prior published studies by Memorial Sloan Kettering Cancer Center collaborators indicate that HSCT patients with a dysbiotic microbiome are at substantially increased risk for bacterial infections and poor ...
MCRB Price Returns
Continue Researching MCRBWant to do more research on Seres Therapeutics Inc's stock and its price? Try the links below:
Seres Therapeutics Inc (MCRB) Stock Price | Nasdaq
Seres Therapeutics Inc (MCRB) Stock Quote, History and News - Yahoo Finance
Seres Therapeutics Inc (MCRB) Stock Price and Basic Information | MarketWatch